Combined our results with a previous report, which demonstrated high catalase activity in circulating cells from untreated CML [34], we propose that targeting catalase may improve the efficacy of As2O3 in CML cells. This evidence concerns the gene CAT and chronic myelogenous leukemia, BCR-ABL1 positive.